Clinical analysis of viral hepatitis B recurrence after liver transplantation for HBV-related liver diseases
10.3760/cma.j.issn.0254-1785.2018.03.006
- VernacularTitle:肝移植受者乙型肝炎复发的因素分析
- Author:
Xiaochuan YAN
1
;
Lei GENG
;
Lin ZHOU
;
Shusen ZHENG
Author Information
1. 浙江大学附属第一医院外科部肝胆胰外科
- Keywords:
Liver transplantation;
Viral hepatitis B;
Nucleoside analogue
- From:
Chinese Journal of Organ Transplantation
2018;39(3):154-157
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the recurrence risks of viral hepatitis B (VHB) after liver transplantation for hepatitis B virus (HBV)-related liver diseases.Methods A total of 599 patients undergoing liver transplantation due to HBV-related liver disease [hepatic cellular cancer (HCC),decompensated liver cirrhosis (DLC),acute liver failure (ALF)] were included in this study.All patients included in this study have been followed up for at least 12 month for liver biochemistry and HBV testing,altogether with the clinic presentation and outcomes.Treatment protocols about prevention of VHB recurrence in perioperative period and after liver transplantation,the time interval and influence factors of VHB recurrence,and the disease prognosis were analyzed.Results Of the 599 patients,36 cases of VHB recurrence were observed.The rate of VHB recurrence was 7.2％ (23/319),5.6％ (13/232) and 0 (0/48) for HCC,DLC and ALF,respectively.The rates of VHB recurrence were 2.3％,5.5％,6％ for 1 year,5 years and 8 years,respectively.The rate of VHB recurrence in the lamivudine group was significantly higher than in enticavir group and combination therapy group [16.5％ (22/133),2.9％ (8/280),and 3.2％ (6/186),respectively,P＜0.05 for all].Conclusion HCC and DLC as liver transplant indications are independent risk factors for VHB recurrence after liver transplant.For liver transplant patients with HBV-related liver disease,entecavir monotherapy and combination therapy (lamivudine and adefovir,or tenofovir) are both more effective on the prophylaxis of VHB recurrence than lamivudine monotherapy.
